Latest Articles about FPRXEN-USWed, 23 Jul 2014 12:02:43 -0400357007
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D_alMJiUcWg/bristol-myers-cytomx-therapeutics-join-forces-analyst-blog-cm357007
Bristol-Myers & CytomX Therapeutics Join Forces - Analyst BlogBristol Myers Squibb Company ( BMY ) entered into a strategic global research collaboration and license deal with biotech company, CytomX Therapeutics, for the discovery, development and commercialization of new drugs against multiple immuno oncology targets with the help<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/D_alMJiUcWg" height="1" width="1"/>Wed, 28 May 2014 14:17:42 -04002014-05-28T14:17:42-04:00http://www.nasdaq.com/article/bristol-myers-cytomx-therapeutics-join-forces-analyst-blog-cm357007346722
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pfdK79s19m0/bristol-myers-samsung-biologics-extend-ties-analyst-blog-cm346722
Bristol-Myers, Samsung BioLogics Extend Ties - Analyst BlogBristol Myers Squibb Company ( BMY ) expanded its existing manufacturing agreement with Samsung BioLogics. As per the new deal, Samsung will be manufacturing several biologic medicines for Bristol Myers at its manufacturing site in Incheon, South<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/pfdK79s19m0" height="1" width="1"/>Wed, 23 Apr 2014 19:52:58 -04002014-04-23T19:52:58-04:00http://www.nasdaq.com/article/bristol-myers-samsung-biologics-extend-ties-analyst-blog-cm346722343134
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zgYbgmvyknQ/-should-five-prime-therapeutics-fprx-be-on-your-radar-now-tale-of-the-tape-cm343134
Should Five Prime Therapeutics (FPRX) Be On Your Radar Now? - Tale of the TapeOpening It can be very difficult to find companies that are both flying under the radar, and still might have potential for gains. Many times, stocks are off investors' radar screens for a reason, though there are some hidden<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/zgYbgmvyknQ" height="1" width="1"/>Thu, 10 Apr 2014 09:44:25 -04002014-04-10T09:44:25-04:00http://www.nasdaq.com/article/-should-five-prime-therapeutics-fprx-be-on-your-radar-now-tale-of-the-tape-cm343134341381
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/skpClMPeYPI/earnings-estimates-moving-higher-for-five-prime-fprx-time-to-buy-tale-of-the-tape-cm341381
Earnings Estimates Moving Higher for Five Prime (FPRX): Time to Buy? - Tale of the TapeFive Prime Therapeutics, Inc. (FPRX) is a biomedical company that could be an interesting play for investors. That is because, not only does the stock have decent short term momentum, but it is seeing solid activity on the earnings<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/skpClMPeYPI" height="1" width="1"/>Fri, 04 Apr 2014 09:37:28 -04002014-04-04T09:37:28-04:00http://www.nasdaq.com/article/earnings-estimates-moving-higher-for-five-prime-fprx-time-to-buy-tale-of-the-tape-cm341381339412
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rZccyjNU4Lk/bristol-myers-deal-overshadows-q4-loss-at-five-prime-analyst-blog-cm339412
Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst BlogFive Prime Therapeutics, Inc. ( FPRX ) has been in the news over the past few days. Investors at Five Prime, which went public in September last year, had plenty to cheer when the company inked a<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/rZccyjNU4Lk" height="1" width="1"/>Thu, 27 Mar 2014 13:30:15 -04002014-03-27T13:30:15-04:00http://www.nasdaq.com/article/bristol-myers-deal-overshadows-q4-loss-at-five-prime-analyst-blog-cm339412336253
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iQtVo1nDuaU/bristol-myers-five-prime-join-forces-shares-up-analyst-blog-cm336253
Bristol-Myers, Five Prime Join Forces, Shares up - Analyst BlogIn a bid to strengthen its oncology pipeline, Bristol Myers Squibb Company ( BMY ) joined forces with Five Prime Therapeutics, Inc. ( FPRX ). The oncology deal grants Bristol Myers access to Five Prime's immuno<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/iQtVo1nDuaU" height="1" width="1"/>Tue, 18 Mar 2014 14:08:30 -04002014-03-18T14:08:30-04:00http://www.nasdaq.com/article/bristol-myers-five-prime-join-forces-shares-up-analyst-blog-cm336253336136
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Hz7v3TSbQxQ/five-prime-therapeutics-fprx-surges-stock-moves-226-higher-tale-of-the-tape-cm336136
Five Prime Therapeutics (FPRX) Surges: Stock Moves 22.6% Higher - Tale of the TapeFive Prime Therapeutics, Inc. ( FPRX ) was a big mover last session, as the company saw its shares rise by roughly 23% on the day. The move came on solid volume too with far more shares<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Hz7v3TSbQxQ" height="1" width="1"/>Tue, 18 Mar 2014 11:10:27 -04002014-03-18T11:10:27-04:00http://www.nasdaq.com/article/five-prime-therapeutics-fprx-surges-stock-moves-226-higher-tale-of-the-tape-cm336136277724
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BrsEA9EwbD4/five-prime-therapeutics-prices-ipo-at-13-within-the-range-cm277724
Five Prime Therapeutics prices IPO at $13, within the rangeFive Prime Therapeutics, which is developing protein therapeutics for cancers and autoimmune diseases, raised $62 million by offering 4.8 million shares at $13, within the range of $12 to $14. Five Prime Therapeutics plans to list on<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/BrsEA9EwbD4" height="1" width="1"/>Tue, 17 Sep 2013 21:57:12 -04002013-09-17T21:57:12-04:00http://www.nasdaq.com/article/five-prime-therapeutics-prices-ipo-at-13-within-the-range-cm277724273271
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2q5lZlblrJc/us-ipo-recap-benefitfocus-six-others-set-terms-as-calendar-rebuilds-cm273271
US IPO Recap: Benefitfocus, six others set terms as calendar rebuildsJoined by fast growing SaaS company Benefitfocus ( BNFT ), four biotechs led the way in rebuilding the US IPO calendar last week. Matching the total for all of August, seven companies set terms for deals, all<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/2q5lZlblrJc" height="1" width="1"/>Mon, 09 Sep 2013 16:57:54 -04002013-09-09T16:57:54-04:00http://www.nasdaq.com/article/us-ipo-recap-benefitfocus-six-others-set-terms-as-calendar-rebuilds-cm273271272588
http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B2AzNHji-UA/biotech-five-prime-therapeutics-sets-terms-for-52-million-ipo-cm272588
Biotech Five Prime Therapeutics sets terms for $52 million IPOFive Prime Therapeutics, a clinical stage biotech developing protein therapeutics, announced terms for its IPO on Wednesday. The San Francisco, CA based company plans to raise $52 million by offering 4.0 million shares at a price range<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/B2AzNHji-UA" height="1" width="1"/>Wed, 04 Sep 2013 19:34:38 -04002013-09-04T19:34:38-04:00http://www.nasdaq.com/article/biotech-five-prime-therapeutics-sets-terms-for-52-million-ipo-cm272588